← board
NAGE
distress 1/10 · well-funded / low risk$3.31-3%today-71% from 52w high
Lead: Parkinson's disease · est. market ~$6B (approx, global)
Revenue
$31M
Liquidity
$67M
Runway
—
Shares 1y
0%
Price & events
-47.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.6%
1D
-2.6%
1W
-2.1%
1M
-30.0%
3M
-44.9%
6M
-66.4%
1Y
+7.8%
2Y
-64.9%
5Y
-30.3%
All
Overview
- Market Cap
- $263.62M
- Volume
- 31.81K
- 52 Week Range
- $3.19 – $11.50
- Total Shares
- 79.64M
- Float Shares
- 59.59M
- Short %
- 8.47%
- % Held by Insiders
- 29.26%
- % Held by Institutions
- 47.33%
- RVOL
- 0.05x
- Beta
- 2.08
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- 2026Guided 40%readoutPhase 3Niagen · Topline data from Phase III NOPARK trial in early PD expectedSEC 8-K
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-02-24partnershipSold analytical reference standards and services business to LGC in all-cash transaction.SEC 8-K
- 2025-12-16partnershipNicotinamide Riboside (NR) · QUB assigns all rights in NR patents to Niagen, terminating prior agreements and releasing royalty obligations.SEC 8-K
- 2025-07-08partnershipNiagen · Worldwide exclusive license with Haukeland University Hospital for Parkinson's diseaseSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $12 (+263% upside) · 6 analysts
- 2026-05-11HC Wainwright & Co.Buy
- 2026-05-05Canaccord GenuityBuy
- 2026-03-31Canaccord GenuityBuy
- 2026-03-05Canaccord GenuityBuy
- 2025-11-05Canaccord GenuityBuy
- 2025-08-11HC Wainwright & Co.Buy
Competitors — Parkinson's disease
- DNLIDenali Therapeutics Inc.$3.6B · D2
- SUPNSUPERNUS PHARMACEUTICALS, INC.$2.7B · D0
- MPLTMapLight Therapeutics, Inc.$1.5B · D2
- ARVNARVINAS, INC.$525M · D1
- OVIDOvid Therapeutics Inc.$442M · D4
- IKTInhibikase Therapeutics, Inc.$289M · D4
- VYGRVoyager Therapeutics, Inc.$184M · D4
- GANXGain Therapeutics, Inc.$78M · D3
- SERSerina Therapeutics, Inc.$33M · D6
- ALMSALUMIS INC.— · D4
Recent news
- 2026-07-22Niagen Bioscience, Inc. (NAGE) Q1 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-21Niagen Bioscience (NAGE) to Announce Q2 Financial Results on August 4, 2026 - GuruFocus
- 2026-07-21Niagen Bioscience to report Q2 2026 results on August 4 - scanx.trade
- 2026-07-21Niagen Bioscience (NAGE) to Announce Q2 Financial Results on August 4, 2026 - GuruFocus
- 2026-07-21Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Business Wire
- 2026-07-17SteelPeak Wealth LLC Makes New Investment in Niagen Bioscience, Inc. $NAGE - MarketBeat
- 2026-07-16Niagen Bioscience Appoints Abhijit Kale to Lead Global External Research Program - citybiz
- 2026-07-16Niagen Bioscience appoints Abhijit Kale as research director - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.